Training and Support for Hybrid Closed-Loop Therapy.
J Diabetes Sci Technol
MetadataShow full item record
Boughton, C. K., Hartnell, S., Allen, J. M., Fuchs, J., & Hovorka, R. (2022). Training and Support for Hybrid Closed-Loop Therapy.. J Diabetes Sci Technol, 16 (1), 218-223. https://doi.org/10.1177/1932296820955168
Hybrid closed-loop therapy is an emerging technology transforming the management of type 1 diabetes (T1D). Research studies demonstrate glycemic and quality of life benefits of hybrid closed-loop therapy for people with T1D. Translating these outcomes into standard clinical practice is critical for reimbursement and improving access to this technology.High-quality training is essential for achieving optimal outcomes with hybrid closed-loop therapy. Basic diabetes skills and tasks are as important, or even more important, with closed-loop therapy than with standard insulin therapy and need to be reiterated. Establishing expectations of hybrid closed-loop therapy clearly at the outset promotes long-term usage and optimal outcomes.We share key aspects of training and support for users of commercially available hybrid closed-loop systems and consider who may benefit from this technology.
Commentaries, artificial pancreas, hybrid closed-loop, training, type 1 diabetes
Department of Health (via National Institute for Health Research (NIHR)) (EME 14/23/09)
Wellcome Trust (100574/B/12/Z)
Helmsley Charitable Trust (#2016PG-T1D046)
Cambridge University Hospitals NHS Foundation Trust (CUH) (146281)
Wellcome Trust (100574/Z/12/Z)
External DOI: https://doi.org/10.1177/1932296820955168
This record's URL: https://www.repository.cam.ac.uk/handle/1810/332478